PDCD1 and hepatocellular carcinoma: Treatments combining the three therapeutic modalities (programmed cell death protein-1 [PD-1] inhibitors, TKIs, and HAIC) might have a synergistic effect in treating u-HCC given their different modes of action, as previously reported [10–13].